Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary

NCT07761429 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT07761429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07761429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 8, 2026
Completion date
April 30, 2028
Enrollment
402 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of unknown primary site